An 800-kb Region of Deletion at 13q14 in Human Prostate and Other Carcinomas

• Published in: Genomics (San Diego, Calif.) Vol. 77; no. 3; pp. 135 - 144
• Main Authors: Chen, Ceshi, Frierson, Henry F, Haggerty, Paul F, Theodorescu, Dan, Gregory, Christopher W, Dong, Jin-Tang
• Format: Journal Article
• Language: English
• Published: San Diego, CA Elsevier Inc 01-10-2001; Elsevier
• Subjects: Adult; Aged; Aged, 80 and over; Alleles; Biological and medical sciences; chromosome 13; Chromosome Deletion; Chromosomes, Human, Pair 13 - genetics; Classical genetics, quantitative genetics, hybrids; Female; Fundamental and applied biological sciences. Psychology; Genes, Tumor Suppressor; Genetics of eukaryotes. Biological and molecular evolution; Homozygote; Human; Humans; Loss of Heterozygosity; Male; Middle Aged; Molecular and cellular biology; Molecular Sequence Data; Neoplasm Transplantation; Neoplasms - genetics; Physical Chromosome Mapping; Prostatic Neoplasms - genetics; Transplantation, Heterologous; Tumor Cells, Cultured; deletion; prostate cancer; chromosome 13; Chromosomal aberration; Human; Carcinoma; Deletion; Abnormal chromosome; Malignant tumor; Prostate
• ISSN: 0888-7543; 1089-8646
• DOI: 10.1006/geno.2001.6631

Deletions of regions at 13q14 have been detected by various genetic approaches in human cancers including prostate cancer. Several studies have defined one region of loss of heterozygosity (LOH) at 13q14 that seems to reside in a DNA segment of 7.1 cM between genetic markers D13S263 and D13S153. To define the smallest region of overlap (SRO) for deletion at 13q14, we first applied tissue microdissection and multiplex PCR to detect homozygous deletion and/or hemizygous deletion at 13q14 in 134 prostate cancer specimens from 114 patients. We detected deletions at markers D13S1227, D13S1272, and A005O48 in 13 (10%) of these tumor specimens. Of the 13 tumors with deletions, 12 were either poorly differentiated primary tumors or metastases of prostate cancer. To fine-map the deletion region, we then constructed a high-resolution YAC/BAC/STS/EST physical map based on experimental and database analyses. Several markers encompassing the deletion region were analyzed for homozygous deletion and/or hemizygous deletion in 61 cell lines/xenografts derived from human cancers of the prostate, breast, ovary, endometrium, cervix, and bladder, and a region of deletion was defined by duplex PCR assay between markers A005X38 and WI-7773. We also analyzed LOH at 13q14 in the 61 cell lines/xenografts using the homozygosity mapping of deletion approach and 26 microsatellite markers. We found 24 (39%) of the cell lines/xenografts to show LOH at 13q14 and defined a region of LOH by markers M1 and M5. Combination of homozygous or hemizygous deletion and LOH results defined the SRO for deletion to be an 800-kb DNA interval between A005X38 and M5. There are six known genes located in or close to the SRO for deletion. This region of deletion is at least 2 Mb centromeric to the RB1 tumor-suppressor gene and the leukemia-associated genes 1 and 2, each of which is located at 13q14. These data suggest that the 800-kb DNA segment with deletion contains a gene whose deletion may be important for the development of prostate and other cancers. This study also provides a framework for the fine-mapping, cloning, and identification of a novel tumor-suppressor gene at 13q14.